Full-text resources of PSJD and other databases are now available in the new Library of Science.
Visit https://bibliotekanauki.pl
Preferences help
Polish version English version Language
enabled [disable] Abstract
Number of results

Results found: 3

Number of results on page
first rewind previous Page / 1 next fast forward last

Search results

Search:
in the keywords:  trifluridine/tipiracil
help Sort By:

help Limit search:
first rewind previous Page / 1 next fast forward last
1
Publication available in full text mode
Content available

Remarkable prolonged progression-free survival time after therapy with trifluridine/ tipiracil. A case report of 57-year-old woman with metastatic colorectal cancer

100%
Orlikowska M.
OncoReview
|
2020
|
vol. 10
|
issue 1
27-30
EN
Colorectal cancer is the second leading cause of cancer-related death worldwide. Trifluridine/tipiracil is a novel orally administered antineoplasmatic thymidine-based nucleoside analog which represents an approved option for the treatment of advanced metastatic colorectal cancer in patients who are refractory, or are not considered candidates for, currently available therapies. In this report, we present a case of chemotherapy using trifluridine/tipiracil confirming the effectiveness of this drug primarily in the term of prolongation of progression free survival.
2
Publication available in full text mode
Content available

Efficacy of trifluridine/tipiracil as IV line chemotherapy in a young woman with metastatic colorectal cancer. A case report

100%
Wiśniowski R.
OncoReview
|
2020
|
vol. 10
|
issue 1
23-26
EN
Colorectal cancer is the most common gastrointestinal malignancy and the third most frequently diagnosed cancer worldwide. Trifluridine/tipiracil represents an approved option for the treatment of advanced metastatic colorectal cancer in patients who are refractory, or are not considered candidates for currently available therapies. We present a case of a young woman with refractory metastatic colorectal cancer treated with this agent as the IV line of chemotherapy in which remarkable prolongation of progression free survival time was observed.
3
Publication available in full text mode
Content available

Chemotherapy with trifluridine/tipiracil prolongs progression-free survival time and improves quality of life A case report of 59-year-old woman with metastatic rectal cancer

88%
Kania-Zembaczyńska B.
OncoReview
|
2020
|
vol. 10
|
issue 1
18-22
EN
The paper presents a clinical case of a patient with a long-term response to IV line chemotherapy with trifluridine/tipiracil. The treatment allowed to maintain a good quality of life with acceptable side effects.
first rewind previous Page / 1 next fast forward last
JavaScript is turned off in your web browser. Turn it on to take full advantage of this site, then refresh the page.